J Rheumatol: Comparison of TNFi monotherapy and combination therapy in psoriasis arthritis

The study aims to explore whether tumor necrosis factor inhibitors (TNFi) combined with conventional synthetic disease-improved anti-rheumatic drugs (csDMARDs) in patients with psoriasis arthritis (PsA) are more effective than TNFi monotherapy and/or improve the survival of TNFi drugssurveyed five PsA bioqueues between 2000 and 2015: ATTRA Registration (Czech Republic), Swiss Clinical Quality Management PsA Registration, Greek Biotherapy Registration (Greece), University of Bari PsA Biologics Database (Italy) and Bath PsA Queue (UK)Use Kaplan-Meier to analyze drug durability and Log-Rank test to analyze whether the survival is equalThe use of logistic regression analysis with a tendency score compares effectivenessA separate analysis was carried out: (a) changes in the DAS-28 rate in the Italian/Swiss consolidated queue;a total of 2,294 patients met the requirements of drug survival analysisPatients who started tNFi-combined MTX treatment in the database had a longer survival period compared to monotherapy (p.0.002), Greece (p.0.021) and Bath (p-0.014), while italian monotherapy had a longer survival period (p.0.030)There was no significant difference in the rate of change in DAS28 between the treatment groups in patients with the Italian/Swiss combined data set (n-1066)Similarly, there was no significant difference in the proportion of HAQ changes when included in the Bath queue (n-1205)compared to TNFi monotherapy, TNFi and csDMARD combination therapy did not affect disease activity or HAQ improvement, but could improve the drug survival of TNFi